BRPI1005828A2 - composição farmacêutica; método para o tratamento ou a profilaxia de uma infecção viral ou doença associada com a mesma; composto; método para a preparação de uma mistura de terc-butil(4e)-4-(hidroximetileno)-5-oxoazepano-1-carboxilato e terc-butil (3e)-3-(hidroximetileno)-4-oxoazepano-1-carboxilato; método para a preparação de uma mistura de terc-butil 3-ciano-2-tioxo-1,2,5,6,8,9-hexaidro-1h-pirido [2,3-d] azepina-7-carboxilato e terc-butil 3-ciano-2-tioxo-1,2,5,7,8,9-hexaidro-6h-pirido [3,2-c] azepina-6-carboxilato; método para a preparação de ácido 3-amino-7-terc-butiloxicarbonil-6,7,8,9-tetraidro-5h-1-tia-7,10-diaza-ciclohepta [f] indeno-2-carboxílico (5-fenil-[1,3,4]tiazol-2-il)-amida; método para a preparação de ácido 3-amino-6,7,8,9-tetraidro-5h-1-tia-7,10-diaza-ciclohepta [f] indeno-2-carboxílico (5-fenil-[1,3,4] tiadiazol-2-il)-amida; método para a preparação de ácido 3-amino-6-tercbutiloxicarbonil-6,7,8,9-tetraidro-5h-1-tia-6,10-diaza-ciclohepta [f] indeno-2-carboxílico (5-fenil-[1,3,4] tiadiazol-2-il)-amida e método para a preparação de ácido 3-amino-6,7,8,9-tetraidro-5h-1-tia-6,10-diaza-ciclohepta [f] indeno-2-carboxílico (5-fenil-[1,3,4] tiadiazol-2-il)-amida - Google Patents
composição farmacêutica; método para o tratamento ou a profilaxia de uma infecção viral ou doença associada com a mesma; composto; método para a preparação de uma mistura de terc-butil(4e)-4-(hidroximetileno)-5-oxoazepano-1-carboxilato e terc-butil (3e)-3-(hidroximetileno)-4-oxoazepano-1-carboxilato; método para a preparação de uma mistura de terc-butil 3-ciano-2-tioxo-1,2,5,6,8,9-hexaidro-1h-pirido [2,3-d] azepina-7-carboxilato e terc-butil 3-ciano-2-tioxo-1,2,5,7,8,9-hexaidro-6h-pirido [3,2-c] azepina-6-carboxilato; método para a preparação de ácido 3-amino-7-terc-butiloxicarbonil-6,7,8,9-tetraidro-5h-1-tia-7,10-diaza-ciclohepta [f] indeno-2-carboxílico (5-fenil-[1,3,4]tiazol-2-il)-amida; método para a preparação de ácido 3-amino-6,7,8,9-tetraidro-5h-1-tia-7,10-diaza-ciclohepta [f] indeno-2-carboxílico (5-fenil-[1,3,4] tiadiazol-2-il)-amida; método para a preparação de ácido 3-amino-6-tercbutiloxicarbonil-6,7,8,9-tetraidro-5h-1-tia-6,10-diaza-ciclohepta [f] indeno-2-carboxílico (5-fenil-[1,3,4] tiadiazol-2-il)-amida e método para a preparação de ácido 3-amino-6,7,8,9-tetraidro-5h-1-tia-6,10-diaza-ciclohepta [f] indeno-2-carboxílico (5-fenil-[1,3,4] tiadiazol-2-il)-amidaInfo
- Publication number
- BRPI1005828A2 BRPI1005828A2 BRPI1005828A BRPI1005828A BRPI1005828A2 BR PI1005828 A2 BRPI1005828 A2 BR PI1005828A2 BR PI1005828 A BRPI1005828 A BR PI1005828A BR PI1005828 A BRPI1005828 A BR PI1005828A BR PI1005828 A2 BRPI1005828 A2 BR PI1005828A2
- Authority
- BR
- Brazil
- Prior art keywords
- tert
- preparation
- cyclohepta
- thia
- diaza
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15613209P | 2009-02-27 | 2009-02-27 | |
PCT/US2010/025183 WO2010099166A1 (en) | 2009-02-27 | 2010-02-24 | Thienopyridine derivatives for the treatment and prevention of dengue virus infections |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI1005828A2 true BRPI1005828A2 (pt) | 2017-07-18 |
Family
ID=42665870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI1005828A BRPI1005828A2 (pt) | 2009-02-27 | 2010-02-24 | composição farmacêutica; método para o tratamento ou a profilaxia de uma infecção viral ou doença associada com a mesma; composto; método para a preparação de uma mistura de terc-butil(4e)-4-(hidroximetileno)-5-oxoazepano-1-carboxilato e terc-butil (3e)-3-(hidroximetileno)-4-oxoazepano-1-carboxilato; método para a preparação de uma mistura de terc-butil 3-ciano-2-tioxo-1,2,5,6,8,9-hexaidro-1h-pirido [2,3-d] azepina-7-carboxilato e terc-butil 3-ciano-2-tioxo-1,2,5,7,8,9-hexaidro-6h-pirido [3,2-c] azepina-6-carboxilato; método para a preparação de ácido 3-amino-7-terc-butiloxicarbonil-6,7,8,9-tetraidro-5h-1-tia-7,10-diaza-ciclohepta [f] indeno-2-carboxílico (5-fenil-[1,3,4]tiazol-2-il)-amida; método para a preparação de ácido 3-amino-6,7,8,9-tetraidro-5h-1-tia-7,10-diaza-ciclohepta [f] indeno-2-carboxílico (5-fenil-[1,3,4] tiadiazol-2-il)-amida; método para a preparação de ácido 3-amino-6-tercbutiloxicarbonil-6,7,8,9-tetraidro-5h-1-tia-6,10-diaza-ciclohepta [f] indeno-2-carboxílico (5-fenil-[1,3,4] tiadiazol-2-il)-amida e método para a preparação de ácido 3-amino-6,7,8,9-tetraidro-5h-1-tia-6,10-diaza-ciclohepta [f] indeno-2-carboxílico (5-fenil-[1,3,4] tiadiazol-2-il)-amida |
Country Status (12)
Country | Link |
---|---|
US (2) | US9301949B2 (pt) |
EP (2) | EP3181568A1 (pt) |
JP (3) | JP5854841B2 (pt) |
KR (1) | KR20110136819A (pt) |
CN (2) | CN104856991A (pt) |
AP (1) | AP3069A (pt) |
AU (1) | AU2010218152B2 (pt) |
BR (1) | BRPI1005828A2 (pt) |
CA (1) | CA2753421A1 (pt) |
IL (1) | IL214825A0 (pt) |
MX (1) | MX2011008988A (pt) |
WO (1) | WO2010099166A1 (pt) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010099166A1 (en) * | 2009-02-27 | 2010-09-02 | Siga Technologies, Inc. | Thienopyridine derivatives for the treatment and prevention of dengue virus infections |
JP6042331B2 (ja) | 2010-07-23 | 2016-12-14 | プレジデント アンド フェローズ オブ ハーバード カレッジ | プロテアソーム活性を向上させる三環系化合物 |
NZ609564A (en) | 2010-10-26 | 2015-06-26 | Presidio Pharmaceuticals Inc | Inhibitors of hepatitis c virus |
JP2014528412A (ja) * | 2011-09-30 | 2014-10-27 | キネタ・インコーポレイテツド | 抗ウイルス化合物 |
WO2013112706A1 (en) | 2012-01-25 | 2013-08-01 | Proteostasis Therapeutics, Inc. | Proteasome activity modulating compounds |
WO2013163466A1 (en) * | 2012-04-25 | 2013-10-31 | Presidio Pharmaceuticals, Inc. | Inhibitors of hepatitis c virus |
CA2881351A1 (en) | 2012-09-07 | 2014-03-13 | Novartis Ag | Indole carboxamide derivatives and uses thereof |
US10471082B2 (en) | 2012-10-23 | 2019-11-12 | Georgetown University | Flavivirus protease inhibitors |
JP2016501883A (ja) * | 2012-12-07 | 2016-01-21 | シガ テクノロジーズ,インコーポレーテッド | デングウイルス感染症の治療及び予防のためのチエノピリジン誘導体 |
US9073946B2 (en) * | 2013-01-15 | 2015-07-07 | Kineta, Inc. | Anti-viral compounds |
US20160074373A1 (en) * | 2013-01-23 | 2016-03-17 | The University Of Chicago | Methods and compositions for inhibiting human copper trafficking proteins atox1 and ccs |
CN105418635A (zh) * | 2015-12-25 | 2016-03-23 | 上海应用技术学院 | 一种噻吩并吡啶类医药中间体的合成方法 |
EP3414252B1 (en) * | 2016-02-12 | 2022-07-06 | Valo Health, Inc. | Thienopyridine carboxamides as ubiquitin-specific protease inhibitors |
ES2763274T3 (es) | 2016-02-12 | 2020-05-27 | Forma Therapeutics Inc | Carboxamidas de tienopirazina como inhibidores de la proteasa específica de la ubiquitina |
CN105832734B (zh) * | 2016-03-31 | 2018-05-04 | 南通江海港建设工程有限公司 | 一种化合物在增加血小板浓度药物中的用途 |
CN105769866B (zh) * | 2016-03-31 | 2018-05-04 | 南通江海港建设工程有限公司 | 一种化合物在增加血小板浓度药物中的用途 |
US10689394B2 (en) | 2016-06-14 | 2020-06-23 | The University Of Tokyo | Thieno[2,3-b]pyridine derivative, quinoline derivative, and use thereof |
MX2019012257A (es) | 2017-04-26 | 2019-12-16 | Basilea Pharm Int Ag | Procesos para la preparacion de furazanobencimidazoles y formas cristalinas de estos. |
AU2018316254B2 (en) | 2017-08-11 | 2022-07-14 | Valo Health, Inc. | Carboxamides as ubiquitin-specific protease inhibitors |
EP3704126A4 (en) | 2017-11-03 | 2020-12-09 | Université de Montréal | COMPOUNDS AND THEIR USE IN THE EXPANSION OF STEM CELLS AND / OR PROGENITOR CELLS |
CN108178764A (zh) * | 2018-01-09 | 2018-06-19 | 天津科技大学 | 呋喃并[2,3-b]吡啶类化合物及无金属催化的合成方法 |
CN111920811B (zh) * | 2018-06-13 | 2021-09-21 | 四川轻化工大学 | 一种治疗抗痛风、抗高尿酸血症的药物组合物ⅲ |
CR20200618A (es) * | 2018-06-19 | 2021-01-21 | Novartis Ag | Derivados de tetrahidrotienopiridina n-sustituidos y sus usos |
CN109705136B (zh) * | 2018-12-10 | 2020-08-21 | 济南大学 | 乙酰胆碱酯酶抑制剂及其应用 |
WO2020236688A1 (en) * | 2019-05-22 | 2020-11-26 | Merck Sharp & Dohme Corp. | Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes |
AU2021326457A1 (en) * | 2020-08-10 | 2023-03-16 | Dana-Farber Cancer Institute, Inc. | Fused tricyclic pyrimidine-thieno-pyridine small molecule inhibitors of ubiquitin-specific protease 28 |
US20240139209A1 (en) * | 2021-02-17 | 2024-05-02 | Seoul National University R&Db Foundation | Pharmaceutical composition for preventing or treating dengue fever |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
WO1996009296A1 (fr) | 1994-09-22 | 1996-03-28 | Rational Drug Design Laboratories | Derive d'arylthiadiazole et agent antiviral le contenant |
DK1159279T3 (da) | 1999-03-09 | 2003-02-17 | Upjohn Co | 4-Oxo-4,7-dihydro-thieno[2,3-b]pyridin-5-carboxamider som antivirale midler |
US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
CA2377649C (en) | 2002-03-20 | 2009-02-03 | Ibm Canada Limited-Ibm Canada Limitee | Dynamic cluster database architecture |
US20040063744A1 (en) | 2002-05-28 | 2004-04-01 | Tao Wang | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides |
CA2514466C (en) | 2003-02-19 | 2015-05-26 | Yale University | Anti-viral nucleoside analogs and methods for treating viral infections, especially hiv infections |
US7202363B2 (en) | 2003-07-24 | 2007-04-10 | Abbott Laboratories | Thienopyridine and furopyridine kinase inhibitors |
GB0323810D0 (en) * | 2003-10-10 | 2003-11-12 | Cancer Rec Tech Ltd | Pyridothiophene compounds |
WO2005058315A1 (en) | 2003-12-12 | 2005-06-30 | Ribapharm, Inc. | Novel heterocyclic compounds as ikk2 inhibitors with anti-hbv activity |
US7875604B2 (en) * | 2004-02-04 | 2011-01-25 | University Of Virginia Patent Foundation | Compounds that inhibit HIV particle formation |
WO2006019832A1 (en) | 2004-07-22 | 2006-02-23 | Ptc Therapeutics, Inc. | Thienopyridines for treating hepatitis c |
WO2006010567A1 (de) * | 2004-07-23 | 2006-02-02 | Curacyte Discovery Gmbh | INHIBITOREN DER PHOSPHODIESTERASE 4 UND TNFα-FREISETZUNG |
SE0403171D0 (sv) | 2004-12-23 | 2004-12-23 | Astrazeneca Ab | New compounds |
US7465742B2 (en) | 2005-02-11 | 2008-12-16 | Huanming Chen | Heterocyclic compounds having anti-HBV activity |
DE102005009440A1 (de) | 2005-03-02 | 2006-09-07 | Merck Patent Gmbh | Thienopyridinderivate |
JP2006298909A (ja) | 2005-03-25 | 2006-11-02 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
CA2603322C (en) | 2005-03-31 | 2014-12-16 | Janssen Pharmaceutica N.V. | Bicyclic pyrazole compounds as antibacterial agents |
ES2389964T3 (es) | 2005-07-29 | 2012-11-05 | Janssen R&D Ireland | Inhibidores macrocíclicos del virus de la hepatitis C |
EA013475B1 (ru) | 2005-07-29 | 2010-04-30 | Тиботек Фармасьютикалз Лтд. | Макроциклические ингибиторы вируса гепатита с |
DE102006013957A1 (de) | 2006-03-27 | 2007-10-04 | Bayer Healthcare Aktiengesellschaft | Substituierte N-Benzyl-N-phenylbenzolsulfonamide |
EP2018384A2 (en) | 2006-05-17 | 2009-01-28 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Pyrimidine low molecular weight ligands for modulating hormone receptors |
WO2008100867A2 (en) * | 2007-02-12 | 2008-08-21 | Intermune, Inc. | Novel inhibitors hepatitis c virus replication |
AU2008345225A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
US20130129677A1 (en) | 2009-02-27 | 2013-05-23 | Siga Technologies, Inc. | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections |
WO2010099166A1 (en) | 2009-02-27 | 2010-09-02 | Siga Technologies, Inc. | Thienopyridine derivatives for the treatment and prevention of dengue virus infections |
-
2010
- 2010-02-24 WO PCT/US2010/025183 patent/WO2010099166A1/en active Application Filing
- 2010-02-24 AU AU2010218152A patent/AU2010218152B2/en not_active Ceased
- 2010-02-24 CN CN201510156180.7A patent/CN104856991A/zh active Pending
- 2010-02-24 MX MX2011008988A patent/MX2011008988A/es active IP Right Grant
- 2010-02-24 CN CN201080016715.6A patent/CN102395273B/zh not_active Expired - Fee Related
- 2010-02-24 US US13/203,351 patent/US9301949B2/en not_active Expired - Fee Related
- 2010-02-24 EP EP17150913.6A patent/EP3181568A1/en not_active Withdrawn
- 2010-02-24 JP JP2011552100A patent/JP5854841B2/ja not_active Expired - Fee Related
- 2010-02-24 BR BRPI1005828A patent/BRPI1005828A2/pt not_active Application Discontinuation
- 2010-02-24 AP AP2011005901A patent/AP3069A/xx active
- 2010-02-24 EP EP10746743.3A patent/EP2400845B1/en not_active Not-in-force
- 2010-02-24 CA CA2753421A patent/CA2753421A1/en not_active Abandoned
- 2010-02-24 KR KR1020117022169A patent/KR20110136819A/ko active IP Right Grant
-
2011
- 2011-08-25 IL IL214825A patent/IL214825A0/en unknown
-
2014
- 2014-03-19 JP JP2014056274A patent/JP5956490B2/ja not_active Expired - Fee Related
-
2016
- 2016-02-08 US US15/017,748 patent/US20160152635A1/en not_active Abandoned
- 2016-03-01 JP JP2016038962A patent/JP2016145226A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2016145226A (ja) | 2016-08-12 |
IL214825A0 (en) | 2011-11-30 |
KR20110136819A (ko) | 2011-12-21 |
US20160152635A1 (en) | 2016-06-02 |
MX2011008988A (es) | 2011-12-16 |
AP3069A (en) | 2014-12-31 |
CN102395273A (zh) | 2012-03-28 |
AU2010218152B2 (en) | 2015-04-09 |
AP2011005901A0 (en) | 2011-10-31 |
US20120022046A1 (en) | 2012-01-26 |
JP2012519174A (ja) | 2012-08-23 |
JP5956490B2 (ja) | 2016-07-27 |
AU2010218152A1 (en) | 2011-09-08 |
EP2400845B1 (en) | 2017-02-22 |
EP3181568A1 (en) | 2017-06-21 |
JP5854841B2 (ja) | 2016-02-09 |
CN102395273B (zh) | 2015-05-20 |
US9301949B2 (en) | 2016-04-05 |
JP2014141506A (ja) | 2014-08-07 |
EP2400845A1 (en) | 2012-01-04 |
CN104856991A (zh) | 2015-08-26 |
CA2753421A1 (en) | 2010-09-02 |
WO2010099166A1 (en) | 2010-09-02 |
EP2400845A4 (en) | 2012-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI1005828A2 (pt) | composição farmacêutica; método para o tratamento ou a profilaxia de uma infecção viral ou doença associada com a mesma; composto; método para a preparação de uma mistura de terc-butil(4e)-4-(hidroximetileno)-5-oxoazepano-1-carboxilato e terc-butil (3e)-3-(hidroximetileno)-4-oxoazepano-1-carboxilato; método para a preparação de uma mistura de terc-butil 3-ciano-2-tioxo-1,2,5,6,8,9-hexaidro-1h-pirido [2,3-d] azepina-7-carboxilato e terc-butil 3-ciano-2-tioxo-1,2,5,7,8,9-hexaidro-6h-pirido [3,2-c] azepina-6-carboxilato; método para a preparação de ácido 3-amino-7-terc-butiloxicarbonil-6,7,8,9-tetraidro-5h-1-tia-7,10-diaza-ciclohepta [f] indeno-2-carboxílico (5-fenil-[1,3,4]tiazol-2-il)-amida; método para a preparação de ácido 3-amino-6,7,8,9-tetraidro-5h-1-tia-7,10-diaza-ciclohepta [f] indeno-2-carboxílico (5-fenil-[1,3,4] tiadiazol-2-il)-amida; método para a preparação de ácido 3-amino-6-tercbutiloxicarbonil-6,7,8,9-tetraidro-5h-1-tia-6,10-diaza-ciclohepta [f] indeno-2-carboxílico (5-fenil-[1,3,4] tiadiazol-2-il)-amida e método para a preparação de ácido 3-amino-6,7,8,9-tetraidro-5h-1-tia-6,10-diaza-ciclohepta [f] indeno-2-carboxílico (5-fenil-[1,3,4] tiadiazol-2-il)-amida | |
TW200745069A (en) | Novel 1,4-benzothiazepine 1,1-dioxide derivative with improved properties, process for its preparation, medicaments comprising this compound and its use | |
MY192883A (en) | 2-(morpholin-4-yl)-l,7-naphthyridines | |
BRPI0909985A2 (pt) | Composição farmacêutica e método para o tratamento ou profilaxia de uma infecção viral ou doença associada à mesma | |
PL2080516T3 (pl) | Zastosowanie pochodnych izotiocyjanianowych jako środków przeciwko szpiczakowi | |
BRPI1009034A2 (pt) | composição farmacêutica e método para o tratamento ou profilaxia de uma infecção viral ou doença associada a mesma | |
NZ610104A (en) | Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio) acetic acid and uses thereof | |
WO2007025897A3 (en) | Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives | |
EP2415749A4 (en) | NEW SALVIANOLIC ACID CONNECTION L, PREPARATION METHOD AND USE | |
EA018193B3 (ru) | Соединения и фармацевтические композиции для снижения уровня мочевой кислоты | |
WO2007020213A3 (en) | Thiazolyl piperidine derivatives useful as h3 receptor modulators | |
BRPI0514692A (pt) | inibidores do receptor sigma | |
BRPI0610907A2 (pt) | composto ou precursores hidrolisÁveis in vivo ou sal farmaceuticamente aceitÁvel do mesmo, mÉtodos de tratamento ou profilaxia de uma doenÇa ou condiÇço na qual a modulaÇço do receptor de mch1 É benÉfica e de tratamento ou profilaxia de doenÇas, composiÇço farmacÊutica, e, uso de um composto | |
NZ595314A (en) | PHARMACEUTICAL COMPOSITIONS comprising (1S)-1,5-anhydro-1-[5-(4-ethoxybenzy1)-2-methoxy-4- methylpheny1]-1-thio-D-glucitol or a pharmaceutically acceptable salt thereof or a hydrate of the compound or the salt; and metformin. | |
JO2941B1 (en) | Preliminary dipeptide-like drugs and their use | |
BR112012021364A2 (pt) | "compostos cicloalquila contendo tienopirimidinas e composições farmacêuticas". | |
WO2009015812A3 (de) | Prodrugs des 2-amino-6- ( { [2- (4-chlorphenyl) -1, 3-thiaz0l-4-yl] methyl}thio) -4- [4- ( 2 -hydroxyethoxy) phenyl] pyridin-3, 5-dicarbonitrils | |
WO2008098985A3 (en) | Pharmaceutical composition for the treatment of il-8 mediated diseases | |
WO2008053446A3 (en) | Benzoxazepine compounds, their preparation and use | |
HK1146049A1 (en) | Isoxazole derivatives as modulators of 11-beta-hydroxysteroid dehydrogenase type 1 | |
MX2012003007A (es) | Sulfonamidas como inhibidores de las proteinas de la familia bcl-2 para el tratamiento de cancer. | |
BRPI1011768A2 (pt) | agentes para o tratamento e/ou profilaxia de um distúrbio, e de uma doença, composição farmacêutica, kit, derivado de tiazol, composto, combinação, e, uso de um derivado de tiazol | |
BR112012020557A8 (pt) | formas cristalinas de 4-{[9-cloro-7-(2-flúor-6-metoifenil)-5h-pirimido[5,4-d][2]benzazepin-2-il]amino}-2-metoxibenzoato de sódio | |
NZ596154A (en) | Cyclic compound having substituted phenyl group | |
BRPI0912388A2 (pt) | composto, forma cristalina, processo para preparar compostos, composição farmacêutica, e, uso de um composto, e, método para o tratamento ou profilaxia de doenças |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B12F | Other appeals [chapter 12.6 patent gazette] | ||
B15I | Others concerning applications: loss of priority | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A01N 43/42 , A61K 31/44 Ipc: A61K 31/44 (2006.01), A61K 31/675 (2006.01), A61K |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |